METABOLIC DISORDERS
Greater BMD after 1 year for ALN/D5600 compared to calcitriol treatment in osteoporosis
Osteoporos Int. 2015 Sep;26(9):2365-74.219 postmenopausal Chinese women with osteoporosis were randomized to receive one of two medications: a weekly dose of alendronate sodium with vitamin D3 (ALN/D5600) or a daily dose of calcitriol. The purpose of the study was to determine if ALN/D5600 provided greater benefits for bone mineral density and other measures of osteoporosis compared to calcitriol and to assess the safety of alendronate treatment. ALN/D5600 resulted in significantly greater increases in bone mineral density, serum 25(OH)D, and reductions in biochemical markers of bone turnover in comparison to calcitriol, at up to 1-year follow-up. ALN/D5600 also had a higher rate of drug-related adverse events, but the number of serious adverse events was similar between groups.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
